Product Description
Mechanisms of Action: Epinine Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Italy | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: John Landers
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Glaucoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12611001191987 |
ACTRN12611001191987 | P4 |
Completed |
Glaucoma |
2013-07-29 |
2024-08-29 |
Treatments |
|
2009-015916-16 |
Predicting Glaucoma Progression | P4 |
Terminated |
Glaucoma |
2011-08-24 |
2022-03-13 |
Treatments |
|
ACTRN12615000767505 |
ACTRN12615000767505 | P4 |
Not yet recruiting |
Glaucoma |
None |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/03/2021 |
PubMed |
Severe Hypotony Maculopathy in Anterior Uveitis Associated with Hodgkin Lymphoma. |
|
08/06/2020 |
PubMed |
Uveitis-induced Refractory Ocular Hypotony Managed with High-dose Latanoprost. |